对于 PROTAC 药物发现的计算方法的进步
Massyel S Martinez-Cortés1, Carlos A Velázquez-Martínez2, José L Medina-Franco1
1DIFACQUIM Research Group, Department of Pharmacy, School of Chemistry, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Drug discovery today
|February 19, 2026
概括
向蛋白解酶的仿真体 (PROTACs) 通过降解向蛋白来提供一种新的药物发现方法. 本综述详细介绍了帮助 PROTAC 设计,优化和临床翻译的计算工具.
科学领域:
- 药物发现 药物发现 药物发现
- 药用化学 医学化学
- 计算化学的计算化学
背景情况:
- 化向化体 (PROTACs) 是药物发现的重大进步,提供向蛋白质降解.
- 由于其复杂的结构和非传统的类似药物的特性,PROTACs存在独特的设计和优化挑战.
研究的目的:
- 为支持 PROTAC 开发的计算进步提供全面的概述.
- 突出了PROTAC设计的关键方面,包括弹头和链接器选择,三元复杂建模,降解效率预测和ADMET配置文件的工具.
- 讨论目前的局限性和未来的方向,以提高PROTAC设计和加速临床翻译.
主要方法:
- 对PROTAC开发中的计算工具最近文献的审查.
- 计算方法的分类,包括化学信息学,结构生物信息学,分子建模和机器学习.
- 对特定的PROTAC设计元素和物业预测工具的分析.
主要成果:
- 识别适用于PROTAC研究的各种计算资源.
- 计算工具的演示,以协助弹头/链接器设计和三元复杂模型.
- 突出降解效率和ADMET属性的预测能力.
结论:
- 计算策略对于克服 PROTAC 设计挑战至关重要.
- 化学信息学,生物信息学和机器学习方面的进步加速了PROTAC的发展.
- 增强的计算方法是提高PROTAC设计效率和临床翻译的关键.
相关概念视频
Protein-protein Interfaces
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a polypeptide...
Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Protein-Drug Binding: Determination Methods
Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


